

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Health Technology Appraisal

## Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Alliance Pharmaceuticals Ltd (amantadine)</li> <li>• GlaxoSmithKline (zanamivir)</li> <li>• Roche Products Ltd (oseltamivir)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Sick Children</li> <li>• Action Heart</li> <li>• African HIV Policy Network (AHPN)</li> <li>• Age Concern England</li> <li>• Association for Children with Life Threatening or Terminal Conditions (ACT)</li> <li>• Asthma UK</li> <li>• Black and Ethnic Minority Diabetes Association</li> <li>• British Cardiac Patients Association</li> <li>• British Cardiovascular Society</li> <li>• British Kidney Patient Association</li> <li>• British Lung Foundation</li> <li>• Children with Leukaemia</li> <li>• Children's Heart Federation</li> <li>• Chinese National Healthy Living Centre</li> <li>• CLIC Sargent</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Diabetes UK</li> <li>• Equalities National Council</li> <li>• Gift – The Children's Transplant Charity</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• National Public Health Service for Wales</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Alliance Pharmaceuticals Ltd (amantadine)</li> <li>• GlaxoSmithKline (zanamivir)</li> <li>• Roche Products Ltd (oseltamivir)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research</li> <li>• Institute for Ageing and Health</li> <li>• Juvenile Diabetes Research Foundation</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of the Elderly</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the appraisal of amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• HEART UK</li> <li>• Help the Aged</li> <li>• Kidney Alliance</li> <li>• Little Hearts Matter</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• NAM Publications</li> <li>• National Kidney Federation (UK)</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Terrence Higgins Trust</li> <li>• Tiny Tickers</li> <li>• Transplant Support Network</li> <li>• UK Coalition of People Living with HIV and AIDS</li> <li>• UK Public Health Association</li> <li>• Wellchild</li> <li>• Black Health Agency</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Service to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Paediatric Respiratory Society</li> <li>• British Thoracic Society</li> <li>• Faculty of Public Health Medicine</li> <li>• General Practice Airways Group (GPIAG)</li> <li>• Health Protection Agency</li> <li>• Institute for Ageing and Health</li> <li>• National Association of Primary Care</li> <li>• National Heart Forum (UK)</li> <li>• National Pharmacy Association (NPA)</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul>	<p><u>Assessment team</u></p> <ul style="list-style-type: none"> <li>• NHS Centre for Reviews &amp; Dissemination and Centre for Health Economics - York</li> <li>• National Coordinating Centre for Health Technology Assessment</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• (none)</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• (none)</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the appraisal of amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Surgeons</li> <li>• Royal Institute for Public Health And Hygiene</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• UK Primary Immunodeficiency Network</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• British Paediatric Immunity, Allergy and Infection Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Cornwall and the Isles of Scilly PCT</li> <li>• Department of Health</li> <li>• Dudley PCT</li> <li>• Welsh Assembly Government</li> </ul>	

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the appraisal of amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

Issue date: September 2007

Page 3 of 5

**Definitions:**Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the appraisal of amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

## Manufacturer table

The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic.

<b>Consultees</b>	
<b>Manufacturer</b>	<b>Generic Name</b>
Alliance Pharmaceuticals Ltd	amantadine
GlaxoSmithKline	zanamivir
Roche Products Ltd	oseltamivir
<b>Commentators</b>	
<b>Manufacturer</b>	<b>Generic Name</b>
Alliance Pharmaceuticals Ltd	amantadine
GlaxoSmithKline	zanamivir
Roche Products Ltd	oseltamivir

National Institute for Health and Clinical Excellence

Provisional matrix of consultees and commentators for the appraisal of amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)

Issue date: September 2007

Page 5 of 5